top of page

Unnatural Products has built its expertise in developing macrocyclic peptides. It had already landed four major partnerships before raising its series B in March

  • Apr 23
  • 1 min read

Co-Founder & CEO Cameron Pye walks us through the science of macrocyclic peptides, and discusses the for partnerships (BridgeBio, argenx, Merck, and Novartis). The company raised a $45M series B in March.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page